Quote | Biofrontera Inc. Warrants (NASDAQ:BFRIW)
Last: | $0.06 |
---|---|
Change Percent: | 0.0% |
Open: | $0.0595 |
Close: | $0.06 |
High: | $0.06 |
Low: | $0.0595 |
Volume: | 17,010 |
Last Trade Date Time: | 05/03/2024 03:00:00 am |
News | Biofrontera Inc. Warrants (NASDAQ:BFRIW)
2024-03-18 12:13:02 ET Biofrontera Inc. (BFRI) Q4 2023 Earnings Conference Call March 18, 2024, 10:00 AM ET Company Participants Andrew Barwicki - Barwicki Investor Relations Hermann Luebbert - Chief Executive Officer, Chairman & Founder Fred Leffler - Chief ...
2023-08-11 07:07:52 ET Biofrontera press release ( NASDAQ: BFRI ): Q2 GAAP EPS of -$7.23 misses by $2.62 . Revenue of $5.8M (+31.0% Y/Y) misses by $0.38M . Adjusted EBITDA for the second quarter of 2023 was negative $7.9 million compared with negative $7.1 mill...
Message Board Posts | Biofrontera Inc. Warrants (NASDAQ:BFRIW)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Biofrontera Inc. Warrants Company Name:
BFRIW Stock Symbol:
NASDAQ Market:
WOBURN, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the Company will be participating in Benchmark’s 11th Annual Discovery One-on-One I...
Woburn, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. ("Biofrontera" or the "Company") (NASDAQ: BFRI), announced today that they will be participating in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on ...
WOBURN, Mass., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today the launch of a randomized, double-blind, vehicle-controlled, multicenter Phase 3 clini...